Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Metabolic compensation activates pro-survival mTORC1 signaling upon 3-phosphoglycerate dehydrogenase inhibition in osteosarcoma

Cell Reports(2021)10.1016/j.celrep.2020.108678Source: DataRank Database

Metabolic compensation activates pro-survival mTORC1 signaling upon 3-phosphoglycerate dehydrogenase inhibition in osteosarcoma is a research paper published in Cell Reports (2021). On theSindex it has a DataRank of 0. It has been cited 49 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access49 citations

Download PDF

Cite:

Linked data & code

gen cellosaurus hpa uniprot

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (15 grants)Impact (FWCI 2.99)OA: goldTopics (43)IDs (PubMed, PMC, OpenAlex)Annotations (4)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (16)

Katharine E. Caldwell ORCID,Charles R. Schutt ORCID,Caitlyn B. Brashears ORCID,Bethany C. Prudner ORCID,William Ehrhardt ORCID

Live enrichment

PubMed:33503424 PMC:PMC8552368 OpenAlex:https://openalex.org/W3125100868

National Institutes of Health

Grant: R01CA227115

GlaxoSmithKline

Grant: ACXT3102

Washington University in St. Louis

Grant: P30 CA091842

Washington University in St. Louis

Grant: T32CA009621

NIDDK NIH HHS

Grant: P30 DK056341

NIDDK NIH HHS

Grant: P30 DK020579

National Institutes of Health

Grant: 5P30CA091842-05

Core--Pharmacology Facility

National Institutes of Health

Grant: 2P30DK020579-36

Diabetes Research Center

National Institutes of Health

Grant: 5R01CA227115-02

USING ARGININE METABOLIC THERAPIES FOR SARCOMA

National Institutes of Health

Grant: 2T32CA009621-21

Surgical Oncology Training Grant

Alvin J. Siteman Cancer Center

Washington University School of Medicine in St. Louis

National Cancer Institute

Sarcoma Foundation of America

University of Washington

FWCI

2.99

Citation Percentile

0.9%

Citation Trend

2021

2022

2023

2024

2025

2026

goldLicense: cc-by

journalhttp://www.cell.com/article/S2211124720316673/pdf

publisherhttps://api.elsevier.com/content/article/PII:S2211124720316673?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2211124720316673?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.celrep.2020.108678

repositoryhttps://pubmed.ncbi.nlm.nih.gov/33503424

Fields of Study

Cancer, Hypoxia, and MetabolismBiochemical and Molecular ResearchPI3K/AKT/mTOR signaling in cancer0301 basic medicine0303 health sciences03 medical and health sciences

MeSH Terms

Mechanistic Target of Rapamycin Complex 1Bone NeoplasmsHumansOsteosarcomaSignal TransductionCell Line, TumorPhosphoglycerate Dehydrogenase

Keywords

mTORC1Cancer researchSerineOsteosarcomaMethionineMetabolic pathwayBiologySignal transductionCell growthEnzymeCell biologyBiochemistryAmino acidPI3K/AKT/mTOR pathwayMethotrexatelipid metabolismSerine BiosynthesisOne-carbon MetabolismPhgdhPerhexilineGatorSamtorTumorBone NeoplasmsMechanistic Target of Rapamycin Complex 1ArticleCell LineCell Line, TumorHumansPhosphoglycerate Dehydrogenase

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

Metabolic compensation activates pro-survival mTORC1 signaling upon 3-phosphoglycerate dehydrogenase inhibition in osteosarcoma

FAIR Checklist

Authors (16)

Funding (15 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)